Hostname: page-component-745bb68f8f-d8cs5 Total loading time: 0 Render date: 2025-01-22T10:52:53.983Z Has data issue: false hasContentIssue false
  • English
  • Français

The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes

Published online by Cambridge University Press:  15 May 2009

J. R. Williams ,
D. J. Nokes ,
G. F. Medley  and
R. M. Anderson
J. R. Williams
Affiliation:
Wellcome Centre for Epidemiology of Infectious Disease, Department of Zoology, University of Oxford, South Parks Road, Oxford OX1 3PS.
D. J. Nokes
Affiliation:
Wellcome Centre for Epidemiology of Infectious Disease, Department of Zoology, University of Oxford, South Parks Road, Oxford OX1 3PS.
G. F. Medley
Affiliation:
Ecosystems Analysis and Management Group, Department of Biological Sciences, University of Warwick, Coventry CV7 7AL
R. M. Anderson
Affiliation:
Wellcome Centre for Epidemiology of Infectious Disease, Department of Zoology, University of Oxford, South Parks Road, Oxford OX1 3PS.
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Complex hepatitis B (HBV) epidemiology makes it difficult to evaluate and compare effectiveness of different immunization policies. A method for doing so is presented using a mathematical model of HBV transmission dynamics which can represent universal infant and adolescent vaccination strategies and those targeted at genito-urinary (GU) clinic attenders and infants born to infectious mothers. Model structure, epidemiological underpinning, and parameterization, are described. Data from the UK National Survey of Sexual Attitudes and Lifestyles is used to define patterns of sexual activity and GU clinic attendance; data deficiencies are discussed, in particular that of UK seroprevalence of HBV markers stratified by age, sex, and risk factors. General model predictions of endemic HBV marker prevalence in homosexual and heterosexual populations seem consistent with published UK data. The simulations exhibit non-linearities in the impact of different vaccination strategies. Estimated number of carriers prevented per vaccine dose for each strategy provides a measure of costs and benefits, varying temporally over the course of a programme, and with level of vaccine coverage. Screening before vaccination markedly increases payback per dose in homosexuals but not in heterosexuals; mass infant vaccination gives the poorest effectiveness ratio and vaccination of infants after antenatal screening the best; in general, increasing vaccine coverage yields lower pay-back per dose. The model provides a useful framework for evaluating costs and benefits of immunization programmes, but for precise quantitative comparison more UK epidemiological data is urgently needed.

Type
Research Article
Information
Epidemiology & Infection , Volume 116 , Issue 1 , February 1996 , pp. 71 - 89
Copyright
Copyright © Cambridge University Press 1996

References

1.Sherlock, S. Hepatitis B: the disease. Vaccine 1990; 8 (Suppl.): 6–9.CrossRefGoogle ScholarPubMed
2.Edmund, WJ, Medley, GF, Nokes, DJ, Hall, AJ, Whittle, HC. The influence of age on the development of the hepatitis B carrier state. Proc R Soc Lond B 1993; 253: 197–201.Google Scholar
3.World Health Organisation. Hepatitis B: Acute viral hepatitis B: laboratory reports 1985–1988. Weekly Epidemiol Rec 1990; 65: 38–41.Google Scholar
4.Derso, A, Boxall, EH, Tarlow, MJ, Flewett, TH. Transmission of HBsAg from mother to infant in four ethnic groups. BMJ 1978; 1: 949–52.CrossRefGoogle ScholarPubMed
5.Collins, M, Heptonstall, J. Occupational acquisition of acute hepatitis B infection by health care workers: England and Wales. 1985–1993. Commun Dis Rep; 4: R153–5.Google Scholar
6.Joint Committee on Vaccination and Immunisation. Immunisation against infectious disease. London: HMSO, 1992.Google Scholar
7.Ghendon, Y. WHO strategy for the global elimination of new cases of hepatitis B. Vaccine 1990; 8 (Suppl.): 129–33.CrossRefGoogle ScholarPubMed
8.Salleras, L, Bruguera, M, Vidal, J et al. , Adolescent hepatitis B vaccination programme in Catalonia. In: Bennett, DL, ed. Proceedings of the conference on the control of hepatitis B: the role of prevention in adolescence. London, 1991; 81–90.Google Scholar
9.Plaitano, S, Pasquini, P, Sagliocca, L, Mele, A. Hepatitis B vaccination programme in Italy. In; Bennett, DL, ed. Proceedings of the conference on the control of hepatitis B: the role of prevention in adolescence. London, 1991; 75–79.Google Scholar
10.Bloom, BS, Hillman, AL, Fendrick, AM, Schwartz, JS. A reappraisal of Hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med 1993; 118: 298–306.CrossRefGoogle ScholarPubMed
11.Asch, DA. Cost and effectiveness of hepatitis B immunization. Ann Intern Med 1993; 119: 536–7.CrossRefGoogle ScholarPubMed
12.Anderson, RM, May, RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press, 1991.CrossRefGoogle Scholar
13.Fine, PEM. Herd immunity: history, theory, practice. Epidemiol Rev 1993; 15: 265–302.CrossRefGoogle ScholarPubMed
14.Anderson, RM, Medley, GF, Nokes, DJ. Preliminary analyses of the predicted impacts of various vaccination strategies on the transmission of the hepatitis B virus. In: Bennett, DL, ed. Proceedings of the conference on the control of hepatitis B: the role of prevention in adolescence. London, 1991; 95–130.Google Scholar
15.Johnson, AM, Wadsworth, J, Wellings, K, Field, J, Bradshaw, S. Sexual attitudes and lifestyles. Oxford: Blackwell Scientific Publications, 1994.Google Scholar
16.Banatvala, JE, Chrystie, IL, Palmer, SJ, Kenny, A. Retrospective study of HIV, hepatitis B, and HTLV-1 infection at a London antenatal clinic. Lancet 1990; 335: 859–60.CrossRefGoogle Scholar
17.Bhatti, N, Gilson, RJC, Beecham, M et al. , Failure to deliver hepatitis B vaccine: confessions from a genitourinary medicine clinic. BMJ 1991; 303: 97–101.CrossRefGoogle ScholarPubMed
18.Hart, GJ, Dawson, J, Fitzpatrick, RM et al. , Risk behaviour, anti-HIV and anti-hepatitis B core prevalence in clinic and non-clinic samples of gay men in England. 1991–1992. AIDS 1993; 7: 863–9.CrossRefGoogle ScholarPubMed
19.Coleman, JC, Evans, BA, Thornton, A, Zuckerman, AJ. Homosexual hepatitis. J Infect 1979; 1: 61–6.CrossRefGoogle Scholar
20.Brook, MG, Lever, AML, Kelly, D et al. , Antenatal screening for hepatitis B is medically and economically effective in the prevention of vertical transmission: Three years experience in a London Hospital. Quart J Med 1989; 71: 313–17.Google Scholar
21.Evans, BA, McCormack, SM, Bond, RA, MacRae, KD, Thorp, RW. Human immunodeficiency virus infection, hepatitis B virus infection, and sexual behaviour of women attending a genitourinary medicine clinic. BMJ 1988; 296: 473–5.CrossRefGoogle ScholarPubMed
22.Lim, KS, Catterall, RD, Simon, R, Dane, DS, Briggs, M, Tedder, RS. A reservoir of hepatitis B. J Infect 1979; 1: 163–70.CrossRefGoogle Scholar
23.Barbara, JAJ, Howell, DR, Cleghorn, TE, Cameron, CH, Briggs, M, Dane, DS. A comparison of different methods of screening blood donations for HBsAg. Vox Sanguinis 1977; 32: 4–9.CrossRefGoogle ScholarPubMed
24.King, R, Johnson, PJ, White, YS, Smith, HM, Williams, R. Frequency of asymptomatic hepatitis types B and C in an inner city community and relation to possible risk factors. Quart J Med 1991; 80: 641–649.Google Scholar
25.Loveday, C, Mercey, D. The prevalence of human retroviral infections in female patients attending a central London sexually transmitted disease clinic: 1985–1990. Genitourin Med 1993; 69: 31–4.Google ScholarPubMed
26.Smith, HM, Alexander, GJM, Webb, G, McManus, T, McFarlane, IG, Williams, R. Hepatitis B and delta virus infection among [at risk] populations in south east London. J Epidemiol Commun Hlth 1992; 46: 144–7.CrossRefGoogle ScholarPubMed
27.Kitchen, AD, Harrison, TJ, Meacock, TJ, Zuckerman, AJ, Harrison, JF. Incidence and significance of hepatitis B core antibody in a healthy donor population. J Med Virol 1988; 25: 69–75.CrossRefGoogle Scholar
28.Redeker, AG, Mosley, JW, Gocke, DJ, McKee, AP, Pollack, W. Hepatitis B immune globulin as a prophylactic measure for spouses exposed to acute type B hepatitis. New Eng J Med 1975; 293: 1055–9.CrossRefGoogle ScholarPubMed
29.Alward, WLM, McMahon, BJ, Hall, DB, Heyward, WL, Francis, DP, Bender, TP. The long term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985; 151: 604–9.CrossRefGoogle Scholar
30.World Bank. World Development Report 1993: Investing in health. New York: Oxford University Press Inc, 1993.Google Scholar
31.Williams, JR, Anderson, RM. Mathematical models of the transmission dynamics of human immunodeficiency virus in England and Wales: mixing between different risk groups. J R Statist Soc A 1994; 157: 69–87.CrossRefGoogle Scholar